In addition, cell-based strategies using peptide vaccination with a RHAMM-derived, highly immunogenic peptide, termed RHAMM R3, has proven safe and effective at generating CD8+ RHAMM-specific T cell cytotoxic cellular responses and antitumor activity in patients with AML, myelodysplastic syndrome, multiple myeloma, and, more recently, chronic lymphocytic leukemia in phase I/II trials (393, 399) (Table 4). The gene discussed is HMMR; the disease is AL amyloidosis.